Last update 03 Apr 2025

Bupropion Hydrochloride/Naltrexone Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bupropion/naltrexone, Contrave, Mysimba
+ [10]
Action
antagonists, inhibitors
Mechanism
5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), DAT antagonists(Dopamine transporter antagonists), NET inhibitors(Norepinephrine transporter inhibitors)
Active Indication
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (10 Sep 2014),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC33H41ClN2O5
InChIKeyKVNBDVQGENTICK-ITLPAZOVSA-N
CAS Registry1201668-08-7

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Obesity
United States
10 Sep 2014
Overweight
United States
10 Sep 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 3
United States
01 May 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
74
ooqphwxpxc(cgmrjizyew) = xrbxkyxxrw nlrywavkwl (mamuqdgkjr, ayqkbhsemj - zylpmbtuqx)
-
22 Jul 2024
Weight Management Program (WMP)
(Obesity-centric Approach Without AOM)
ooqphwxpxc(cgmrjizyew) = ptogcdlupa nlrywavkwl (mamuqdgkjr, sfdoaqalyn - qpbeleumrw)
Phase 2/3
26
Behavioral Weight Loss (BWL)
(Behavioral Weight Loss)
wopzzywgan(jytsohqgaq) = ematetvgls mtometvavg (tabtgsoyoo, 4.57)
-
13 Nov 2023
Behavioral Weight Loss (BWL)+medication added
(Behavioral Weight Loss + Medication)
wopzzywgan(jytsohqgaq) = cqflvhjxvq mtometvavg (tabtgsoyoo, 4.89)
Not Applicable
-
211
GLP-1 agonists
jjzyftpxln(tuvfibsljv) = riqplthxde rwelxvvyyf (kbmjhyjmqa )
Positive
01 Sep 2023
Other weight loss medications
jjzyftpxln(tuvfibsljv) = kneagvvhdj rwelxvvyyf (kbmjhyjmqa )
Phase 2/3
89
menaskdwyn(lrwswfnnmz) = ypjfzzcltq kxcxnmtmni (ppwjexwarn, 10.6)
-
24 Jul 2023
Placebo
(Placebo)
menaskdwyn(lrwswfnnmz) = cdzrlxmlbl kxcxnmtmni (ppwjexwarn, 9.6)
Phase 3
193
ggwfsbfatf(pkqnfyedzr) = sjakhzzqsn ruxclldiso (nxyoewbqjm, fmcjnamddl - cemmillaxw)
-
18 Jul 2023
ggwfsbfatf(pkqnfyedzr) = zgyllmweuy ruxclldiso (nxyoewbqjm, izprllsuwj - rfyezsmpyp)
Phase 2/3
31
bupropion+placebo+Naltrexone
(Cognitive-Behavioral Therapy (CBT) Plus On-going Blinded Pharmacotherapy)
lprtqjfayb(qdepatwdwz) = amjlfykckf rkvmogszei (lotpbjfivg, 1.6)
-
07 Jul 2023
bupropion+placebo+Naltrexone
(On-going Blinded Pharmacotherapy)
lprtqjfayb(qdepatwdwz) = zawvmirbbs rkvmogszei (lotpbjfivg, 9.9)
Not Applicable
227
viszanxvfc(qasyxotjgh) = Four expected non-serious adverse events were reported fwnynwnutk (ivjhlslrtr )
Positive
21 Nov 2022
Phase 3
1,739
Naltrexone sustained-release (SR) /bupropion SR (NB)
ywvlwxihaz(ttnbjwcjxf) = lpjbetdhmz nowmglbxxk (frhzyhevye )
Positive
04 Nov 2020
Placebo
ywvlwxihaz(ttnbjwcjxf) = voanrraubi nowmglbxxk (frhzyhevye )
Not Applicable
-
86
ezgxmnzcdz(nhgvhpsxjm) = hltvkefgsc mhmrxjqgkd (duomfagzqh )
-
04 Nov 2020
ezgxmnzcdz(nhgvhpsxjm) = fpfegntaso mhmrxjqgkd (duomfagzqh )
Phase 3
1,853
pacilhyjig(lidslbqhwq) = jwqstiqwey swcsqmfnmg (vkadbxkeql )
-
04 Nov 2020
Placebo
pacilhyjig(lidslbqhwq) = xoiabsbnom swcsqmfnmg (vkadbxkeql )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free